Compugen Ltd CGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CGEN is a good fit for your portfolio.
News
-
Compugen Reports Third Quarter 2023 Results
-
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
-
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
-
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer
-
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
-
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
-
Compugen to Present at Single Cell Genomics 2023 Meeting
-
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
Trading Information
- Previous Close Price
- $0.83
- Day Range
- $0.80–0.81
- 52-Week Range
- $0.53–1.49
- Bid/Ask
- $0.76 / $0.79
- Market Cap
- $71.20 Mil
- Volume/Avg
- 62,301 / 177,975
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.37
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 69
- Website
- https://www.cgen.com
Valuation
|
Metric
|
CGEN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.34 |
Price/Sales | 9.37 |
Price/Cash Flow | — |
Price/Earnings
CGEN
Financial Strength
|
Metric
|
CGEN
|
|---|---|
Quick Ratio | 5.81 |
Current Ratio | 5.81 |
Interest Coverage | — |
Quick Ratio
CGEN
Profitability
|
Metric
|
CGEN
|
|---|---|
Return on Assets (Normalized) | −37.33% |
Return on Equity (Normalized) | −46.13% |
Return on Invested Capital (Normalized) | −47.92% |
Return on Assets
CGEN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Msy | $438.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dknhzw | $92.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zsyrbv | $91.2 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Kpdljlj | $41.2 Bil | |
MRNA
| Moderna Inc | Tsfxc | $30.5 Bil | |
ARGX
| argenx SE ADR | Fkvqk | $27.2 Bil | |
BNTX
| BioNTech SE ADR | Gbjk | $24.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ymhqdy | $22.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Skqbzl | $17.9 Bil | |
INCY
| Incyte Corp | Hlxdv | $12.4 Bil |